Durability of transgene expression after rAAV gene therapy

por Muhuri, Manish, Levy, Daniel I., Schulz, Martin, McCarty, Douglas, Gao, Guangping
Publicado 2022

Incremental health care resource utilization and expenditures associated with autosomal-dominant polycystic kidney disease

por Iyer, Neeraj N, Vendetti, Nicholas J, Levy, Daniel I, Mardekian, Jack, Mychaskiw, Marko A, Thomas, Joseph
Publicado 2018

Rationale for using centralized transduction inhibition assays in three phase 3 rAAV gene therapy clinical trials

por Schulz, Martin, Bashirians, George, Cheng, Seng H., Levy, Daniel I., Lundie, Mark, Wilcox, Lisa, Winburn, Ian, Somanathan, Suryanarayan
Publicado 2023

A Retrospective Study of Clinical and Economic Burden of Focal Segmental Glomerulosclerosis (FSGS) in the United States

por Kalantar-Zadeh, Kamyar, Baker, Christine L., Copley, J. Brian, Levy, Daniel I., Berasi, Stephen, Tamimi, Nihad, Alvir, Jose, Udani, Suneel M.
Publicado 2021

PODO: Trial Design: Phase 2 Study of PF-06730512 in Focal Segmental Glomerulosclerosis

por Beck, Laurence H., Berasi, Stephen P., Copley, J. Brian, Gorman, Donal, Levy, Daniel I., Lim, Chay Ngee, Henderson, Joel M., Salant, David J., Lu, Weining
Publicado 2021